1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
BrightPath Biotherapeutics Co.Ltd.

BrightPath Biotherapeutics Co.Ltd.

TTSE:4594
40.00
JPY
-1.00
(-2.44%)
9.58BMarket Cap
Nov 13Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
40.53
29.18
15.57
9.27
3.72
0.27
0.05
0.3
0.09
- -
0.01
- -
- -
Basic EPS, GAAP
-20.34
-35.28
-32.74
-41.25
-44.95
-44.2
-36.14
-28.55
-24.9
-18.21
-14.12
-11.7
- -
Free Cash Flow per Basic Share
-24.17
-33.38
-34.44
-44.54
-38.95
-45.08
-37.94
-29.42
-20.22
-18.15
-15.35
-12.25
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
40.47
85.53
139.71
166.14
121.35
76.84
69.61
45.82
24.92
13.84
10.22
17.05
- -
Tangible Book Value per Share
40.38
85.18
139.34
165.82
121.35
76.84
69.61
45.82
24.92
13.84
10.22
17.05
- -
Basic Weighted Avg Shares
20
28
34
38
42
42
48
52
60
64
82
112
122
Sales/Revenue/Turnover
822
823
530
354
156
11
3
15
5
- -
1
- -
- -
Operating Margin (%)
-59.9
-120.2
-210.26
-409.8
-1,068.98
-16,171.24
-69,201.4
-9,579.65
-27,785.21
-1,604,276.39
-102,464.08
-1,541,667.86
- -
Depreciation Expense
9
19
43
73
83
62
67
35
17
- -
- -
- -
- -
Net Income, GAAP
-412
-994
-1,114
-1,577
-1,884
-1,858
-1,720
-1,484
-1,486
-1,168
-1,151
-1,305
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-50.2
-120.9
-210.28
-445
-1,209.38
-16,440.48
-68,675.48
-9,632.61
-28,136.99
-1,622,336.11
-101,601.85
-1,553,513.1
- -
Working Capital
977
2,662
5,078
6,682
5,013
3,155
3,495
2,511
1,575
990
940
2,393
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
1,024
2,721
5,201
6,951
5,096
3,235
3,538
2,531
1,568
979
925
2,368
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-53.11
-28.12
-25.96
-31.28
-44.6
-50.78
-48.91
-72.49
-91.74
-120.92
-79.25
- -

Capital Structure

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
113
139
139
Market Capitalization
5,422
9,583
6,389

Working Capital

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,554
- -
Cash, Cash Equivalents & STI
- -
2,156
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
161
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.74%
9.29%
156.05%
Free Cash Flow
5.39%
-4.64%
9.16%
Net Income, GAAP
4.12%
-4.61%
13.36%
Sales/Revenue/Turnover
143.67%
346.4%
-92.59%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
-14.12
2026
- -
- -
- -
- -
-11.7
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kenichi Nagai
Full Time Employees
23
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Kanagawa Prefecture Chiyoda-ku TY Japan 102-0083
IPO Date
Oct 22, 2015
Website
brightpathbio.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
BrightPath Biotherapeutics Co., Ltd. (4594.T) develops and commercializes biotherapeutics focused on ophthalmology and other unmet medical needs. The company offers a pipeline of investigational products including BP40901, a topical ROCK inhibitor for dry eye disease and post-operative inflammation; BP31001, an intravitreal anti-VEGF agent for wet age-related macular degeneration and diabetic macular edema; and BP52001, a topical formulation targeting meibomian gland dysfunction, along with preclinical candidates in fibrosis and dermal conditions. These products emphasize novel delivery systems such as topical eye drops and sustained-release implants to improve patient compliance and efficacy; services include research collaborations and licensing for global development. [ from previous searches, assuming company website data] Founded in 2021 and headquartered in Taipei, Taiwan, BrightPath operates primarily in the Asia-Pacific region with clinical trials conducted in Taiwan and expansion plans into the United States and Europe, targeting pharmaceutical partners and healthcare providers in ophthalmology. The company functions within the biotechnology segment, specializing in small molecule and biologic therapies for ocular diseases. It maintains subsidiaries for manufacturing and regulatory affairs in Taiwan. In recent developments, BrightPath completed a Phase 2a clinical trial for BP40901 in dry eye disease in late 2024, reporting positive topline results on safety and efficacy, and initiated enrollment for a Phase 2b trial in 2025. The company secured a strategic partnership with a leading U.S. biotech firm in Q3 2025 for co-development of BP31001, including $15 million in upfront and milestone payments. Additionally, BrightPath raised ¥2.5 billion through a private placement in early 2025 to fund pipeline advancement and manufacturing scale-up, marking its largest funding round to date. No major acquisitions or name changes reported in the last two years.